Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06911502 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
A Phase 3 study of Follicular Lymphoma, sponsored by Celgene.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06911502 is a Phase 3 study of Follicular Lymphoma that is actively recruiting participants, run by Celgene. The registered enrollment target is 400 participants, above the 131-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (205% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06911502, a Phase 3 study of Follicular Lymphoma, is actively recruiting participants, sponsored by Celgene.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Lenalidomide
- DRUG Golcadomide
Study Locations (20)
Florida
- Local Institution - 0008 - Jacksonville
- Local Institution - 0214 - Tampa
- Local Institution - 0217 - Tampa
Alabama
- Local Institution - 0225 - Birmingham
- Infirmary Cancer Care - Mobile
California
- City of Hope Comprehensive Cancer Center - Duarte
- UCSF Helen Diller Medical Center at Parnassus Heights - San Francisco
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital - Marietta
- Southeastern Regional Medical Center - Newnan
Iowa
- Local Institution - 0253 - Iowa City
- Local Institution - 0243 - Waukee
Maryland
- Local Institution - 0023 - Baltimore
- Greater Baltimore Medical Center - Towson
Massachusetts
- Local Institution - 0145 - Boston
- Local Institution - 0244 - Boston
Alaska
- Alaska Oncology and Hematology - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-07-28 |
| Est. Completion | 2030-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06911502
The ClinicalTrials.gov registry entry for NCT06911502 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 131-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (205% higher). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06911502 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT06911502 about?
NCT06911502 is a clinical study titled "A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)". The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic the...
What is the current status of trial NCT06911502?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2025-07-28. Estimated completion is 2030-07-31.
What conditions does trial NCT06911502 study?
This clinical trial studies the following conditions: Follicular Lymphoma.
What interventions are being tested in trial NCT06911502?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Lenalidomide (DRUG), Golcadomide (DRUG).
Who is sponsoring clinical trial NCT06911502?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06911502 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
RECRUITING · Phase 3
-
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
ACTIVE NOT RECRUITING · Phase 3
-
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
COMPLETED · Phase 3
-
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.